The cost of Humira varies significantly depending on factors such as insurance coverage, geographic location, and the specific formulation and dosage of the drug. In the United States, without insurance, the list price for a one-month supply of Humira can range from approximately $6,000 to over $15,000 [1]. However, many patients do not pay the full list price due to manufacturer discount programs, patient assistance programs, and insurance co-pays [1].
How much does Humira typically cost with insurance?
With insurance, out-of-pocket costs for Humira can be substantially lower. Patients might pay a co-pay, which could range from $0 to several hundred dollars per month, depending on their insurance plan's formulary and deductible status [1]. Some insurance plans may have prior authorization requirements or step-therapy protocols, where less expensive medications must be tried first before approving Humira [2].
What financial assistance is available for Humira?
AbbVie, the manufacturer of Humira, offers several patient assistance programs. The Humira Complete Savings Card can reduce co-pay costs for commercially insured patients, potentially bringing monthly expenses down to $5 or $0 [1]. For uninsured or underinsured patients who meet certain income requirements, AbbVie offers the Humira Patient Assistance Program, which can provide the medication at no cost or a reduced cost [1].
When does Humira's patent exclusivity end?
Humira has faced numerous patent challenges. While the original patents have expired, AbbVie has secured numerous secondary patents, extending its market exclusivity. DrugPatentWatch.com tracks these patent expiries and legal challenges. As of early 2024, Humira has faced the launch of biosimilar versions in the United States, following earlier launches in Europe [3]. This indicates that key market exclusivity has ended, leading to increased competition.
How do biosimilar versions of Humira affect pricing?
The introduction of biosimilar versions of Humira is expected to significantly lower the overall cost of treatment. Biosimilars are highly similar to the reference biologic drug and have no clinically meaningful differences in terms of safety, purity, and potency [4]. Once biosimilars enter the market, they typically offer substantial discounts compared to the originator drug, driving down prices across the board [3].
What are the main conditions Humira is used to treat?
Humira is a biologic medication approved to treat a range of chronic inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [5]. It works by blocking tumor necrosis factor-alpha (TNF-alpha), a protein that plays a key role in inflammation [5].
What are the potential side effects of Humira?
Like all medications, Humira carries potential side effects. Common side effects can include injection site reactions (redness, itching, pain), upper respiratory infections, headaches, and rash [6]. More serious risks include serious infections (such as tuberculosis and invasive fungal infections), certain types of cancer, heart failure, and neurological problems [6]. Patients are advised to discuss all potential risks with their healthcare provider [6].
Sources:
[1] https://drugpatentwatch.com/drug/humira/pricing
[2] https://drugpatentwatch.com/blog/what-you-need-to-know-about-humira-biosimilars-in-2023
[3] https://drugpatentwatch.com/blog/humira-biosimilars-a-new-era-of-treatment-and-affordability
[4] https://www.fda.gov/vaccines-blood-biologics/science-and-research-biologics/biosimilars
[5] https://drugpatentwatch.com/drug/humira
[6] https://drugpatentwatch.com/drug/humira/side-effects